Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2019; 9(23):6824-6839. doi:10.7150/thno.36739 This issue Cite

Review

PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery

Yvonne H.W. Derks1✉, Dennis W. P. M. Löwik2, J. P. Michiel Sedelaar3, Martin Gotthardt1, Otto C. Boerman1, Mark Rijpkema1, Susanne Lütje4, Sandra Heskamp1

1. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
2. Radboud University Nijmegen, Institute for Molecules and Materials, Systems Chemistry, Nijmegen, The Netherlands
3. Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
4. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

✉ Corresponding author: Yvonne Derks, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA Nijmegen, Phone: +31 (0)24 365 5340, E-mail: yvonne.derksnl

Citation:
Derks YHW, Löwik DWPM, Sedelaar JPM, Gotthardt M, Boerman OC, Rijpkema M, Lütje S, Heskamp S. PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. Theranostics 2019; 9(23):6824-6839. doi:10.7150/thno.36739. https://www.thno.org/v09p6824.htm
Other styles

File import instruction

Abstract

Graphic abstract

Despite recent improvements in imaging and therapy, prostate cancer (PCa) still causes substantial morbidity and mortality. In surgical treatment, incomplete resection of PCa and understaging of possible undetected metastases may lead to disease recurrence and consequently poor patient outcome. To increase the chance of accurate staging and subsequently complete removal of all cancerous tissue, prostate specific membrane antigen (PSMA) targeting agents may provide the surgeon an aid for the intraoperative detection and resection of PCa lesions. Two modalities suitable for this purpose are radionuclide detection, which allows sensitive intraoperative localization of tumor lesions with a gamma probe, and fluorescence imaging, allowing tumor visualization and delineation. Next to fluorescence, use of photosensitizers may enable intraoperative targeted photodynamic therapy to eradicate remaining tumor lesions. Since radiodetection and optical imaging techniques each have their own strengths and weaknesses, a combination of both modalities could be of additional value. Here, we provide an overview of recent preclinical and clinical advances in PSMA-targeted radio- and fluorescence-guided surgery of PCa.

Keywords: PSMA, image-guided surgery, radionuclide, fluorescence, multimodal imaging.

Citation styles

APA
Derks, Y.H.W., Löwik, D.W.P.M., Sedelaar, J.P.M., Gotthardt, M., Boerman, O.C., Rijpkema, M., Lütje, S., Heskamp, S. (2019). PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. Theranostics, 9(23), 6824-6839. https://doi.org/10.7150/thno.36739.

ACS
Derks, Y.H.W.; Löwik, D.W.P.M.; Sedelaar, J.P.M.; Gotthardt, M.; Boerman, O.C.; Rijpkema, M.; Lütje, S.; Heskamp, S. PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. Theranostics 2019, 9 (23), 6824-6839. DOI: 10.7150/thno.36739.

NLM
Derks YHW, Löwik DWPM, Sedelaar JPM, Gotthardt M, Boerman OC, Rijpkema M, Lütje S, Heskamp S. PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. Theranostics 2019; 9(23):6824-6839. doi:10.7150/thno.36739. https://www.thno.org/v09p6824.htm

CSE
Derks YHW, Löwik DWPM, Sedelaar JPM, Gotthardt M, Boerman OC, Rijpkema M, Lütje S, Heskamp S. 2019. PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. Theranostics. 9(23):6824-6839.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use